The HRD Decision-Which PARP Inhibitor to Use for Whom and When.
Elise C. Kohn
S Percy Ivy
Clinical cancer research : an official journal of…
View on PubMed
Abstract & Figures
Rucaparib, a polyADPribose polymerase inhibitor (PARPi), was approved recently for use in women with high-grade serous ovarian cancer (HGSOC). It is now one of three approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome. Clin Cancer Res; 23(23); 7155-7. ©2017 AACRSee related article…
Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
recurrent ovarian epithelial cancer
Sorry, we couldn't extract any citations for this paper.
Sorry, we couldn't extract any references for this paper.
Loading similar papers…
Presentations referencing similar topics